

# Clinical Nephrotoxins

## Renal Injury from Drugs and Chemicals

Third Edition

## TABLE OF CONTENTS

	<b>PREFACE</b>	<b>VIII</b>
	<b>LIST OF CONTRIBUTORS</b>	<b>X</b>
<b>A</b>	<b>GENERAL</b>	<b>1</b>
<b>1</b>	<b>Clinical relevance</b> <i>George A. Porter</i>	3
<b>2</b>	<b>Drug-associated acute kidney injury in the intensive care unit</b> <i>Mitchell H. Rosner and Mark D. Okusa</i>	29
<b>3</b>	<b>Renal handling of drugs and xenobiotics</b> <i>Marc E. De Broe and Françoise Roch-Ramel</i>	43
<b>4</b>	<b>Pharmacological aspects of nephrotoxicity</b> <i>Marisa D. Covington and Rick G. Schnellmann</i>	73
<b>5</b>	<b>Pharmacovigilance: from signal to action</b> <i>Hubert G. Leufkens and Antoine C. Egberts</i>	85
<b>6</b>	<b>Urinary biomarkers and nephrotoxicity</b> <i>William F. Finn and George A. Porter</i>	91
<b>7</b>	<b>Toxin-induced immunological renal disease</b> <i>Lucette Pelletier, Abdelhadi Saoudi and Gilbert Fournié</i>	131
<b>8</b>	<b>Cellular mechanisms of nephrotoxicity</b> <i>Istvan Arany, Gur P. Kaushal, Didier Portilla, Judit Megyesi, Peter M. Price and Robert L. Safirstein</i>	155
<b>9</b>	<b>Animal models for the assessment of acute renal dysfunction and injury</b> <i>Zoltan H. Endre and Charles L. Edelstein</i>	173
<b>10</b>	<b>Renal cell culture models: contribution to the understanding of nephrotoxic mechanisms</b> <i>Paul Jennings, Christian Koppelstätter, Judith Lechner and Walter Pfaller</i>	223
<b>11</b>	<b>Use of dialytic therapies for poisoning</b> <i>James F. Winchester, Nikolas Harbord and Donald A. Feinfeld</i>	251

<b>B</b>	<b>SPECIFIC DRUGS</b>	<b>265</b>
<b>12</b>	<b>Aminoglycosides and vancomycin</b> <i>Brian S. Decker and Bruce A. Molitoris</i>	267
<b>13</b>	<b>Beta-lactam antibiotics</b> <i>Constantin Cojocel</i>	293
<b>14</b>	<b>Amphotericin B</b> <i>Nathalie K. Zgheib, Blair Capitano and Robert A. Branch</i>	323
<b>15</b>	<b>Sulfonamides, sulfadiazine, trimethoprim-sulfamethoxazole, pentamidine, pyrimethamine, dapsone, quinolones</b> <i>Gabriel N. Contreras, Cristiane Mocelin Carvalho, Jorge M. Diego, Decio Carvalho and Isabel Espinal</i>	353
<b>16</b>	<b>Antiviral agents</b> <i>Jeffrey S. Berns, Alden Doyle and Nishaminy Kasbekar</i>	383
<b>17</b>	<b>Analgesics and 5-aminosalicylic acid</b> <i>Monique M. Elseviers and Marc E. De Broe</i>	399
<b>18</b>	<b>Non-steroidal anti-inflammatory drugs</b> <i>Ali J. Olyaei, Andrew Whelton, Til Sturmer and George A. Porter</i>	419
<b>19</b>	<b>Gold salts, D-penicillamine and allopurinol</b> <i>Shiro Ueda and George A. Porter</i>	459
<b>20</b>	<b>Angiotensin I converting enzyme inhibitors and angiotensin II receptor antagonists</b> <i>Paul E. De Jong</i>	481
<b>21</b>	<b>Diuretics and alcohol ingestion</b> <i>Sheldon C. Chaffer and Jules B. Puschett</i>	495
<b>22</b>	<b>Anticancer drugs</b> <i>Corinne Isnard-Bagnis, Vincent Launay-Vacher, Svetlana Karie and Gilbert Deray</i>	511
<b>23</b>	<b>Anesthetic agents</b> <i>Per-Olof Jarnberg</i>	537
<b>24</b>	<b>Bisphosphonates and the kidney</b> <i>Jonathan Green</i>	547
<b>25</b>	<b>Proton pump inhibitors: acute interstitial nephritis and other renal effects</b> <i>Ursula C. Brewster and Mark A. Perazella</i>	567
<b>26</b>	<b>Oral sodium phosphate bowel purgatives and acute phosphate nephropathy</b> <i>Glen S. Markowitz</i>	579
<b>27</b>	<b>Illicit drug abuse and renal disease</b> <i>Cheryl L. Kunis, Nidhi Aggarwal and Gerald B. Appel</i>	595
<b>28</b>	<b>Nephrotoxicity of calcineurin and mTOR inhibitors</b> <i>Emmanuel A. Burdmann and William M. Bennett</i>	617
<b>29</b>	<b>Immunomodulators: interleukins, interferons, and IV immunoglobulin</b> <i>Joris J. Roelofs, Daniel Abramowicz and Sandrine Florquin</i>	683

<b>30</b>	<b>Imaging agents</b>	<b>699</b>
	<i>Christiane M. Erley, Ihab M. Wahba and George A. Porter</i>	
<b>31</b>	<b>Lithium-associated kidney effects</b>	<b>725</b>
	<i>Daniel Batlle, Edgar V. Lerma, Parveen Naaz and Santosh Hakkapakki</i>	
<b>32</b>	<b>Oxalate</b>	<b>749</b>
	<i>Anja Verhulst and Marc E. De Broe</i>	
<b>33</b>	<b>Herbal remedies containing aristolochic acid and mushroom nephrotoxicity</b>	<b>579</b>
	<i>Frédéric Debelle, Marie-Carmen Muniz-Martinez, Jean-Louis Vanherweghem and Joëlle Nortier</i>	
<b>C</b>	<b>ENVIRONMENTAL AND OCCUPATIONAL NEPHROTOXINS</b>	<b>771</b>
<b>34</b>	<b>Lead nephropathy</b>	<b>773</b>
	<i>Richard P. Wedeen</i>	
<b>35</b>	<b>Cadmium-induced renal effects</b>	<b>785</b>
	<i>Gunnar F. Nordberg, Teruhiko Kido and Harry A. Roels</i>	
<b>36</b>	<b>Mercury-induced renal effects</b>	<b>811</b>
	<i>Bruce A. Fowler, Margaret H. Whittaker and Carl-Gustaf Elinder</i>	
<b>37</b>	<b>Organic solvents, silicon-containing compounds and pesticides</b>	<b>827</b>
	<i>Patrick C. D'Haese, Monique M. Elseviers, Muhammed Yaqoob and Marc E. De Broe</i>	
<b>38</b>	<b>Balkan nephropathy</b>	<b>843</b>
	<i>Ljubica Djukanovic and Zoran Radovanovic</i>	
<b>39</b>	<b>Nephrotoxins in Africa</b>	<b>859</b>
	<i>Charles Swanepoel, Marc Blockman and Joe Talmud</i>	
<b>40</b>	<b>Paraphenylene diamine hair dye poisoning</b>	<b>871</b>
	<i>Mohamed I. Hamdouk, Mohamed B. Abdelraheem, Ahbab A. Taha, Mohamed Benghanem and Marc E. De Broe</i>	
<b>D</b>	<b>THE RENAL FAILURE PATIENT</b>	<b>881</b>
<b>41</b>	<b>Trace metal disturbances in end-stage renal failure patients</b>	<b>883</b>
	<i>Patrick C. D'Haese</i>	
<b>42</b>	<b>Smoking and the kidney</b>	<b>895</b>
	<i>Eberhard Ritz</i>	
<b>43</b>	<b>Star fruit</b>	<b>901</b>
	<i>Miguel Moysés Neto, Ruither O. Carolino, Norberto P. Lopes and Norberto Garcia-Cairasco</i>	
<b>44</b>	<b>Drug dosage in renal failure</b>	<b>913</b>
	<i>Ali J. Olyaei and William M. Bennett</i>	
	<b>LIST OF ABBREVIATIONS</b>	<b>945</b>
	<b>INDEX</b>	<b>951</b>

Clinical Nephrotoxins

Renal Injury from Drugs and Chemicals

de Broe, M.E.; Porter, G.A. (Eds.)

2008, XVII, 987 p., Hardcover

ISBN: 978-0-387-84842-6